Tysabri Progressive Multifocal Leukoencephalopathy Attorney: Statute of Limitations for Tysabri in Georgia

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Information to Targeted Risk Assessment

For decades, mass production environments have relied on general health and science information to guide workplace safety protocols. This foundational knowledge has helped establish baseline protections for workers exposed to various substances and conditions. However, as industrial processes evolve, so too must our understanding of specific occupational hazards that may arise from prolonged or concentrated exposure to certain materials. In the context of pharmaceutical manufacturing and healthcare settings, the transition from general health awareness to targeted risk assessment becomes particularly critical. Workers involved in the production, handling, or administration of biologic therapies may encounter unique exposure scenarios that extend beyond routine safety considerations. One such example involves the potential for occupational exposure to medications like Tysabri, which has been associated with progressive multifocal leukoencephalopathy (PML) risk. This shift in focus requires moving from broad health education to a more nuanced examination of how workplace conditions can influence individual vulnerability. The legacy of general health information provides a necessary foundation, but it must be supplemented with specialized knowledge about specific agents and their potential long-term effects. For those in Georgia who have experienced such exposure, understanding the legal timeframe for seeking recourse becomes paramount. The statute of limitations for Tysabri-related claims in Georgia represents a critical consideration for affected individuals navigating the intersection of occupational health and legal accountability.

Understanding Tysabri and Its Association with PML

Tysabri (natalizumab) is a biologic medication approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. The U.S. Food and Drug Administration (FDA) has assigned a Boxed Warning to Tysabri, the agency's most stringent safety alert, due to this risk. The warning states that Tysabri "increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This warning is based on clinical evidence and postmarketing surveillance. PML presents with a range of neurological symptoms that can develop subacutely over weeks to months. Common clinical features include progressive weakness on one side of the body, visual disturbances such as hemianopia, cognitive decline, ataxia, and speech difficulties. Diagnosis typically relies on brain magnetic resonance imaging showing characteristic white matter lesions and detection of JC virus DNA in cerebrospinal fluid via polymerase chain reaction. The condition is often fatal or leads to severe, permanent disability. The FDA-approved prescribing information for Tysabri emphasizes that healthcare professionals should "monitor patients on TYSABRI for any new sign or symptom that may be suggestive of PML" and that "TYSABRI dosing should be withheld immediately at the first sign or symptom suggestive of PML" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Mechanism of PML and Risk Factors

The mechanistic pathway linking Tysabri to PML involves the drug's pharmacological action. Tysabri is a monoclonal antibody that binds to alpha-4 integrins on the surface of immune cells, preventing their migration across the blood-brain barrier into the central nervous system. This reduces inflammatory activity in multiple sclerosis but also impairs normal immune surveillance in the brain. The resulting immunocompromised state allows latent JC virus, which is present in a majority of the population, to reactivate and cause lytic infection of oligodendrocytes, leading to demyelination and the clinical syndrome of PML. The FDA-approved label identifies three key risk factors for PML in Tysabri-treated patients: "the presence of anti-JCV antibodies," "longer treatment duration, especially beyond 2 years," and "prior use of immunosuppressants" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors are used to stratify risk when considering treatment. The adequacy of warnings regarding Tysabri and PML has been a subject of legal scrutiny. The Boxed Warning and the restricted TOUCH Prescribing Program were implemented to mitigate risk. The label states that "patients must be enrolled in the TOUCH Prescribing Program, read the Medication Guide, understand the risks associated with TYSABRI, and complete and sign the Patient Enrollment Form" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, questions may arise about whether patients were adequately informed of the specific magnitude of PML risk, the latency period, and the potential for irreversible harm.

Statute of Limitations for Tysabri Claims in Georgia

The timeline between exposure and documented harm can vary. PML has been reported after a few months to several years of Tysabri treatment. The label notes that for herpes infections, "the duration of treatment with TYSABRI prior to onset ranged from a few months to several years" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962), and a similar range applies to PML. For affected patients in Georgia, attorney-related considerations include the statute of limitations for filing a product liability or medical malpractice claim. In Georgia, the statute of limitations for personal injury claims is generally two years from the date the injury was discovered or reasonably should have been discovered. Given the latency of PML, the discovery date may be when a patient first experiences neurological symptoms or receives a confirmed diagnosis. It is critical for patients and their families to consult with a qualified attorney promptly to assess their specific circumstances and ensure compliance with applicable deadlines. Legal counsel can also evaluate whether the manufacturer provided adequate warnings and whether the treating physician adhered to monitoring and risk mitigation protocols. In summary, Tysabri is associated with a significant risk of PML, a devastating neurological condition. The FDA has mandated strong warnings and a restricted distribution program, but affected patients may still face severe outcomes. Understanding the clinical presentation, risk factors, and legal timelines is essential for those considering or pursuing legal action in Georgia.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Tysabri-related claims in Georgia?

In Georgia, the statute of limitations for personal injury claims, including those related to Tysabri and PML, is generally two years from the date the injury was discovered or reasonably should have been discovered. Due to the latency of PML, the discovery date may be when neurological symptoms first appear or when a diagnosis is confirmed. It is crucial to consult an attorney promptly to ensure compliance with this deadline.

What are the key risk factors for developing PML while on Tysabri?

The FDA-approved label identifies three key risk factors: the presence of anti-JCV antibodies, longer treatment duration (especially beyond 2 years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors help stratify risk when considering Tysabri therapy.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

FDA DailyMed Tysabri Label

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.